- Cella D等人。患者报告用一线Nivolumab Plus Cabozatinib与Sunitinib治疗的晚期肾细胞癌（ARCC）的患者的结果：Checkmate 9er试验。asco Geatitureariarariase癌症研讨会，2011年2月11日至13日。
ASCO GU 2021：肾细胞癌中的鼻腔加上Cavozantinib卓越的临床结果和生活质量
在Mevermate 91er中，用Nivolumab Plus Cabozantib处理的肾细胞癌（RCC）患者均显示出普通initinib治疗的患者的临床结果和卓越的生活质量。checkmate 9er试验（NCT03141177.）是一种第3阶段，开放标签，随机对照试验，研究Nivolumab是否与Cabozantib联合的疗效是一种安全有效的干预，与先前未处理的先进或转移rcc的患者患者中的Sunitinib相比。Although the study’s estimated completion date is not until May 2024, it reached its primary completion date in February 2021. Researchers included patient-reported outcomes (PROs) as an exploratory endpoint, utilizing 2 instruments: the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI-19) and the 3-level version of the EuroQol-5 Dimensions scale (EQ-5D-3L). Participants in both arms of the study were invited to complete the questionnaires at baseline (>90% completion rate) and common on-treatment and follow-up visits (≥80% completion rate). Mixed-model repeated measures were employed to express score changes from baseline to week 91. Kaplan-Meier estimates and Cox proportional hazards models were utilized to predict time to confirmed deterioration. Participants receiving nivolumab plus cabozantinib reported a smaller treatment burden than those receiving sunitinib. They had both a decreased risk of confirmed deterioration as well as a delay in deterioration. Patients in the nivolumab plus cabozantinib arm also consistently demonstrated better FKSI-19, disease-related symptoms (DRS), DRS-physical, DRS-emotional, functional well-being, and EQ-5D-3L scores. The nivolumab plus cabozantinib treatment arm has also demonstrated superior clinical outcomes. After the median follow-up period of 18.1 months, participants in this arm achieved longer periods of progression-free survival, higher overall survival rates, and greater objective response rates than those treated with sunitinib. Overall, these results demonstrated that patients with untreated advanced or metastatic RCC can enjoy both favorable clinical outcomes and an improved quality of life when treated with nivolumab plus cabozantinib instead of sunitinib.